HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it has elected to redeem on March 17, 2023 (the "Redemption Date")...

Related Keywords

San Diego ,California ,United States ,Schottlandt Claudia Styslinger ,Covis Pharma ,Eli Lilly ,Bristol Myers Squibb ,Teva Pharmaceutical ,Nasdaq ,Halozyme Therapeutics Inc ,Pfizer ,Exchange Commission ,York Mellon Trust Company ,Idorsia Pharmaceuticals ,Corporate Communications ,Halozyme Therapeutics ,New York Mellon Trust Company ,Business Day ,Redemption Date ,Conversion Price ,Horizon Therapeutics ,Viiv Healthcare ,Private Securities Litigation Reform Act ,Although Halozyme ,Annual Report ,Quarterly Reports ,Investor Relations ,Nc ,